ArticleNature2025
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers.
Abstract readClinical Trial, Phase I
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 190 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
190citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
190 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Mapping the clinical landscape of multifunctional CAR T cells: Targets, trends, and synergies.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Pooled it
- Strategies and mechanisms for the enhancement of chimeric antigen receptor T-cell functions.Science China. Life sciences · 2026Pooled it
- Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Melanoma: A Systematic Review of Phase One Clinical Trials.Technology in cancer research & treatmentPooled it
- GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.Nature medicine · 2025Trial
- A zinc organic metal skeleton vaccine for lung cancer treatment can stimulate strong innate and adaptive anti-tumor immunity.Materials today. Bio · 2026Article
- Injectable bioinstructive microfoam for rapid bedside/in vivo programming of CAR-T cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells.Cancer immunology research · 2026Article
- Review
- Co-expression of non-signaling CARs enhances EGFRvIII-specific CAR T-cell cytotoxicity against head and neck squamous cell carcinoma.BMC cancer · 2026Article
- Glypican-3-targeted bioconjugates for hepatocellular carcinoma: design, engineering, and translational applications.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- Minor histocompatibility antigen TCR-T.Blood advances · 2026Review
- Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?Nature reviews. Clinical oncology · 2026Article
- Interleukin-15-armored ALPPL2 CAR T cells demonstrate robust preclinical efficacy for solid tumors.Molecular therapy. Oncology · 2026Article
- FOXP1 Knockdown Reprograms Th9 CAR-T Cells to Overcome Antigen Escape.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Scalable generation of hematopoietic stem cell-engineered off-the-shelf mono-specific cytotoxic T cells targeting solid tumors.Cell reports. Medicine · 2026Article
- Targeting Regnase-1 in B7-H3-CAR T cells reprograms the tumor microenvironment and enhances antitumor efficacy for osteosarcoma.Cell reports. Medicine · 2026Article
- Barriers and Blueprints: Next-Generation Engineering Strategies for CAR-T Cell Therapy in Gastrointestinal Tumors.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Recent advances in molecular mechanisms to improve the efficacy of CAR-T cell therapy for viral diseases, cancer, and autoimmune diseases.Stem cell research & therapy · 2026Review
- Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies.Experimental hematology & oncology · 2026Review
- Article
130 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
32 authors.
David SteffinTexas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Nisha GhatwaiTexas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Antonino MontalbanoTexas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Purva RathiTexas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Amy N CourtneyTexas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Azlann B ArnettCenter for Advanced Innate Cell Therapy, Baylor College of Medicine, Houston, TX, USA.
Julien FleurenceTexas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Ramy SweidanCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, TX, USA.
Tao WangDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0003-1957-7160
Huimin ZhangCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, TX, USA.
Prakash MasandDepartment of Radiology, Baylor College of Medicine, Houston, TX, USA.
John M MarisDepartment of Pediatrics, Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-8088-7929
Daniel MartinezPathology and Laboratory Medicine, Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Jennifer PogorilerPathology and Laboratory Medicine, Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Navin VaradarajanWilliam A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA.ORCID 0000-0001-7524-8228
Sachin G ThakkarCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, TX, USA.
Deborah LyonCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, TX, USA.
Natalia LaptevaCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, TX, USA.
Mei ZhuyongCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, TX, USA.
Kalyani PatelDepartment of Pathology, Baylor College of Medicine, Houston, TX, USA.
Dolores Lopez-TerradaDepartment of Pathology, Baylor College of Medicine, Houston, TX, USA.
Carlos A RamosDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Premal LullaDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Tannaz ArmaghanyDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Bambi J GrilleyTexas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Stephen GottschalkDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0003-3991-7468
Gianpietro DottiLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Leonid S MetelitsaTexas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Helen E HeslopDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0001-7049-7698
Malcolm K BrennerDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Pavel SumazinTexas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Andras HeczeyTexas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA. heczey@bcm.edu.ORCID 0000-0002-4263-9115
Funding
Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomesR35CA220500 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI JOHN M MARIS · 2017 to 2026
$8.7MIL-15 and -21 armored GPC3-specific CAR T cells for children with solid tumorsR01CA258866 · NCI · SEATTLE CHILDREN'S HOSPITAL · PI Andras A. Heczey · 2022 to 2026
$3.1MThe Clinical Translational Research Certificate of Added Qualification ProgramT32GM136554 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI Melissa Suter, IGNATIA B VAN DEN VEYVER · 2020 to 2026
$3.0MMusIC: A multi-scale technology for integrating dynamic cellular function and molecular profilesR01GM143243 · NIGMS · UNIVERSITY OF HOUSTON · PI VARADARAJAN, NAVIN · 2021 to 2024
$1.8MPURPOSE OF THE NGVB CONTRACT IS TO CONTINUE SUPPORTING GENE THERAPY RESEARCH.75N92019D00018 · OD · INDIANA UNIVERSITY INDIANAPOLIS · 2019 to 2023
$1.7MDiscovery of chemoresistant tumor subclones in pediatric liver cancersR21CA286257 · NCI · BAYLOR COLLEGE OF MEDICINE · PI SUMAZIN, PAVEL · 2024 to 2025
$413kNCI NIH HHS R01 CA258866NCI NIH HHS R21 CA286257NCI NIH HHS R35 CA220500NHLBI NIH HHS 75N92019D00018NIGMS NIH HHS R01 GM143243NIGMS NIH HHS T32 GM136554
Abstract
Interleukin-15 (IL-15) promotes the survival of T lymphocytes and enhances the antitumour properties of chimeric antigen receptor (CAR) T cells in preclinical models of solid neoplasms in which CAR T cells have limited efficacy
Indexed as
GlypicansImmunotherapy, AdoptiveInterleukin-15NeoplasmsReceptors, Chimeric AntigenT-LymphocytesCohort StudiesCytokine Release SyndromeFemaleHumansInterleukin-6Interleukin-6 InhibitorsMaleMiddle AgedGlypicansGPC3 protein, humanIL15 protein, humanInterleukin-15Interleukin-6Interleukin-6 InhibitorsReceptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.